APA (7th ed.) Citation

Hanna, G., Sanz Garcia, E., Spira, A., Hilton, J., Ferrarotto, R., Zujun, L., . . . Ho, A. (2025). 1018eTiP A phase I trial of RGT-61159, an oral MYB transcription factor inhibitor, for patients with relapsed/refractory (R/R) adenoid cystic carcinoma (ACC) and colorectal cancer (CRC). Annals of Oncology, 36, S662. https://doi.org/10.1016/j.annonc.2025.08.1587

Chicago Style (17th ed.) Citation

Hanna, G.J, et al. "1018eTiP A Phase I Trial of RGT-61159, an Oral MYB Transcription Factor Inhibitor, for Patients with Relapsed/refractory (R/R) Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC)." Annals of Oncology 36 (2025): S662. https://doi.org/10.1016/j.annonc.2025.08.1587.

MLA (9th ed.) Citation

Hanna, G.J, et al. "1018eTiP A Phase I Trial of RGT-61159, an Oral MYB Transcription Factor Inhibitor, for Patients with Relapsed/refractory (R/R) Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC)." Annals of Oncology, vol. 36, 2025, p. S662, https://doi.org/10.1016/j.annonc.2025.08.1587.